Another Upgrade | ARWR Message Board Posts

Arrowhead Pharmaceuticals, Inc.

  ARWR website

ARWR   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  10071 of 10100  at  10/22/2019 9:15:48 AM  by

Manny


Another Upgrade

Arrowhead price target raised to $45 from $32 at Chardan Chardan analyst Keay Nakae increased his price target on Arrowhead shares to $45 from $32 following the company's R&D day last Friday, which he said illustrated the company success in rapidly advancing its pipeline assets. Based on the "benign" safety data and target knockdown data presented thus far from Phase 1 studies of AROANG3 and ARO-APOC3 targeting dyslipidemia and hyper-triglycerides, Nakae has increased his view of the odds of success for these programs to 25%, he noted. Nakae keeps a Buy rating on Arrowhead shares.



     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 4     Views: 286
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board






About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...